

in a human comprising administering a therapeutically effective amount of an antibody which binds HER2 receptor to the human.

38. (NEW) The method of claim 37 wherein the cancer is endometrial cancer.

39. (NEW) The method of claim 37 wherein the cancer is lung cancer.

40. (NEW) The method of claim 37 wherein the cancer is colon cancer.

41. (NEW) The method of claim 37 wherein the cancer is bladder cancer.

42. (NEW) A method for treating cancer characterized by overexpression of HER2 receptor in a mammal comprising administering subcutaneously a therapeutically effective amount of an antibody which binds HER2 receptor to the mammal.

43. (NEW) The method of claim 42 comprising administering subcutaneously to the mammal a formulation comprising the antibody in an amount of about 50mg/mL to about 400mg/mL.

44. (NEW) The method of claim 43 wherein the formulation has been prepared by reconstituting lyophilized antibody in a diluent.

45. (NEW) The method of claim 42 wherein the mammal is a human.

46. (NEW) The method of claim 42 wherein the cancer is selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon and bladder cancer.

47. (NEW) A method for treating a mammal comprising administering a therapeutically effective amount of a stable reconstituted formulation to the mammal in order to treat cancer characterized by overexpression of HER2 receptor in the mammal, wherein the reconstituted formulation comprises an antibody which binds HER2 receptor in an amount of about 50 mg/mL to about 400mg/mL and has been prepared by reconstituting a lyophilized mixture of the antibody and a lyoprotectant in a diluent, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.

48. (NEW) The method of claim 47 wherein the formulation is administered subcutaneously.

49. (NEW) The method of claim 47 wherein the mammal is a human.

50. (NEW) A method for treating ductal carcinoma *in situ* in a human comprising administering a therapeutically effective amount of an antibody which binds HER2 receptor to the human.--

REMARKS

Claims 37-50 have been added herein and basis for these claims can be found at least as follows:

claims 37-41 - page 24, lines 11-14